TORONTO and HAIFA, Israel, Aug. 09, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”) is pleased to announce new data for its ExoPTEN nanodrug, marking a significant step towards commercial-grade manufacturing. Building on the announcement of a new Good Manufacturing Practice (“GMP”) compliant Contract Research Organization (“CRO”) partner, this study assessed the performance of ExoPTEN loaded with small interfering RNA (“siRNA”) produced by the new manufacturer (the “GMP Partner”).

多伦多和以色列海法，2024年8月9日（环球通讯社）--NurExone Biologic Inc.（TSXV:NRX）（OTCQB:NRXBF）（德国：J90）（“公司”或“NurExone”）很高兴宣布其ExoPTEN纳米药物的新数据，标志着朝着商业级生产迈出了重要一步。在宣布新的良好生产规范（“GMP”）合规合同研究组织（“CRO”）合作伙伴的基础上，本研究评估了新制造商（“GMP合作伙伴”）生产的载有小干扰RNA（“siRNA”）的ExoPTEN的性能。

This study focused on the capability of ExoPTEN to biologically target sites of inflammation and injury as evidenced by a high concentration of the drug in damaged tissue. ExoPTEN, loaded with siRNA either from the GMP Partner or from a research grade CRO, was minimally-invasively administered to rats after spinal cord compression injury.

这项研究的重点是ExoPTEN生物学靶向炎症和损伤部位的能力，受损组织中高浓度的药物证明了这一点。在脊髓压迫性损伤后，将装载有来自GMP合作伙伴或研究级CRO的siRNA的ExoPTEN微创施用于大鼠。

The treated rats were compared to each other and to an untreated control group. The homing capacity of ExoPTEN was assessed by evaluating biodistribution of the ExoPTEN three days post-injury and injection. As shown in Figure 1 below, ExoPTEN loaded with siRNA from both sources (A and C) demonstrated exceptional homing capacity to the injured spinal cord, targeting the site of inflammation with precision.

将治疗的大鼠彼此和未治疗的对照组进行比较。通过评估损伤和注射后三天外显子的生物分布来评估外显子的归巢能力。如下图1所示，装载有来自两个来源（A和C）的siRNA的ExoPTEN显示出对受损脊髓的特殊归巢能力，精确地靶向炎症部位。

This resulted in a high concentration of the drug in damaged tissue, further validating the quality of the siRNA produced by the Company’s GMP Partner and the use of NurExone’s exosomes as a drug delivery system. “We are excited by the successful results of the highly complex transfer to a commercial manufacturer,” commented Dr.

这导致受损组织中药物浓度高，进一步验证了该公司GMP合作伙伴生产的siRNA的质量以及NurExone外泌体作为药物输送系统的使用。“我们对高度复杂的转移到商业制造商的成功结果感到兴奋，”Dr。

Noa Avni, Director of Research and Development. “These positive results reinforce our confidence in our ability to produce and scale up our siRNA to meet the q.

诺亚·阿夫尼，研发总监。“这些积极的结果增强了我们对生产和扩大siRNA以满足q的能力的信心。